company background image
MRZM

Marizyme OTCPK:MRZM Stock Report

Last Price

US$0.44

Market Cap

US$18.1m

7D

-11.5%

1Y

-76.1%

Updated

02 Feb, 2023

Data

Company Financials

MRZM Stock Overview

Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business.

MRZM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

New

Notes are coming soon

Marizyme, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Marizyme
Historical stock prices
Current Share PriceUS$0.44
52 Week HighUS$3.25
52 Week LowUS$0.28
Beta0.47
1 Month Change-30.59%
3 Month Changen/a
1 Year Change-76.08%
3 Year Change-84.36%
5 Year Change-4.63%
Change since IPO-74.57%

Recent News & Updates

Recent updates

Shareholder Returns

MRZMUS BiotechsUS Market
7D-11.5%-0.3%1.7%
1Y-76.1%5.3%-9.1%

Return vs Industry: MRZM underperformed the US Biotechs industry which returned 5.3% over the past year.

Return vs Market: MRZM underperformed the US Market which returned -9.1% over the past year.

Price Volatility

Is MRZM's price volatile compared to industry and market?
MRZM volatility
MRZM Average Weekly Movement45.7%
Biotechs Industry Average Movement12.2%
Market Average Movement6.8%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: MRZM is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 46% a week.

Volatility Over Time: MRZM's weekly volatility has increased from 28% to 46% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200711David Barthelhttps://marizyme.com

Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. It offers DuraGraft, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. The company also develops various products using its Krillase protease-based therapeutic platform for treating complex wounds and burns, acute ischemic stroke, deep vein thrombosis, and dissolving plaque and biofilms on teeth.

Marizyme, Inc. Fundamentals Summary

How do Marizyme's earnings and revenue compare to its market cap?
MRZM fundamental statistics
Market CapUS$18.07m
Earnings (TTM)-US$20.12m
Revenue (TTM)US$76.15k

237.3x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MRZM income statement (TTM)
RevenueUS$76.15k
Cost of Revenue-US$61.54k
Gross ProfitUS$137.69k
Other ExpensesUS$20.25m
Earnings-US$20.12m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.49
Gross Margin180.81%
Net Profit Margin-26,417.82%
Debt/Equity Ratio4.5%

How did MRZM perform over the long term?

See historical performance and comparison